@Mozzarc
- Forums
- ASX - By Stock
- PAR
- Paradigm patent rejection
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
2.20%
!
46.5¢

Paradigm patent rejection
-
-
Share
1) Seems to bring up the fact that they want to see ranges of % in terms of postulated benefits:
Ie don't just say Greater than 35% and leave it like that, say 35 - 60% range of benefit could possibly be expected etc. Don't leave it open ended (inferring could be to 100%).
2) Yes prior art, but don't we own the Ghosh Patent effectively?
Felson is also on our books, may need some collaboration if we are to pursue this? Ie we effectively take over his claim/prior art as it were, with his permission?
3) Some paragraph on "The skilled artesian would expect an improvement of symptoms"
Case of obviousness. Not sure about this one and whether we can argue this.
Certainly think it is one for our patent lawyer to go over....I know it is important to get this sewn up...I know we are effectively covered with manufacturing and supply side but always better to have IP in place. Also NGF (patent) overlap is there?
My views.
- There are more pages in this discussion • 28 more messages in this thread...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
46.5¢ |
Change
0.010(2.20%) |
Mkt cap ! $184.8M |
Open | High | Low | Value | Volume |
45.5¢ | 48.0¢ | 44.0¢ | $534.2K | 1.168M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5245 | 45.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
47.0¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 23000 | 0.450 |
1 | 10000 | 0.440 |
1 | 23255 | 0.430 |
2 | 45000 | 0.425 |
2 | 21531 | 0.415 |
Price($) | Vol. | No. |
---|---|---|
0.470 | 10000 | 1 |
0.475 | 13560 | 2 |
0.480 | 90598 | 3 |
0.485 | 10000 | 1 |
0.490 | 18000 | 2 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online